Saif, Muhammad Wasif
Knost, James A.
Chiorean, E. Gabriela
Kambhampati, Siva Rama Prasad
Yu, Danni
Pytowski, Bronislaw
Qin, Amy
Kauh, John S.
O’Neil, Bert H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
https://doi.org/10.1007/s00280-016-3134-3
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 10 May 2016
Accepted: 11 August 2016
First Online: 26 August 2016
Compliance with ethical standards
:
: Dr Saif received research grants from Eli Lilly and Company; served on speaker bureaus for Celgene, Genentech, Ipsen, and Sirtex; and received research funding from Celgene, Genentech, Taiho, Eli Lilly and Company, Merrimack Pharmaceuticals, and Gilead. Dr Chiorean declares her institution received a research grant from Eli Lilly and Company. Dr O’Neil received honorarium from Eli Lilly and Company. Dr Knost has no conflicts to declare. Dr Kambhampati, Dr Yu, Dr Pytowski, Dr Qin, and Dr Kauh are employed by Eli Lilly and Company and are minor stockholders in Eli Lilly and Company.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.